RefludanCompany: Hoechst Marion Roussel
Approval Status: Approved March 1998
Treatment for: heparin-induced thrombocytopenia type II
Refludan has been approved for the treatment of heparin-induced thrombocytopenia type II (HIT type II). HIT type II is a rare, allergy-like adverse reaction to heparin, a standard anticoagulant therapy. HIT type II is characterized by a rapid and serious decline in the blood's platelet count, leading to an increased risk of severe thromboembolic complications.
Refludan Drug Information
The Refludan drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.